Velasco F, Torres A, Rojas R, Alvarez M A, Gomez P, Castillo D
Department of Hematology, Reina Sofia Hospital, Cordoba, Spain.
Haemostasis. 1992;22(3):117-23. doi: 10.1159/000216306.
Plasma concentration of thrombin-antithrombin III complex (TAT), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), PAI-2, D-dimer complex and urokinase-plasminogen activator (u-PA) activity were studied in 30 patients with acute nonlymphoblastic leukemia (ANLL), before and during antileukemic therapy. Fifteen patients showed signs of disseminated intravascular coagulation (DIC), 10 of them classified as M3, 2 as M2 and 3 as M5 subtypes. The initial levels of TAT complex were elevated in all ANLL patients. This increase was more pronounced in patients with DIC (p less than 0.05). TAT increased significantly during the treatment period in all cases. u-PA and PAI-1 levels were elevated but there were no statistically significant differences between patients with and without DIC. PAI-2 levels were below the limit of detection in controls and in patients. However, the initially elevated D-dimer complex levels were significantly higher in DIC cases (p less than 0.01) and they increased during the treatment period. A significant and positive correlation between D-dimer and TAT complex values was found in DIC patients (r = 0.68, p less than 0.001). The high TAT complex and D-dimer levels further increased during chemotherapy treatment strongly suggest a hypercoagulable state with secondary activation of fibrinolysis not severe enough to manifest itself as clinically evident DIC in the majority of cases.
在30例急性非淋巴细胞白血病(ANLL)患者接受抗白血病治疗之前及治疗期间,对其血浆凝血酶 - 抗凝血酶III复合物(TAT)、组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活剂抑制剂1(PAI-1)、PAI-2、D-二聚体复合物及尿激酶型纤溶酶原激活剂(u-PA)活性进行了研究。15例患者出现弥散性血管内凝血(DIC)迹象,其中10例为M3型,2例为M2型,3例为M5型。所有ANLL患者的TAT复合物初始水平均升高。这种升高在DIC患者中更为明显(p<0.05)。在所有病例的治疗期间,TAT均显著升高。u-PA和PAI-1水平升高,但有DIC和无DIC的患者之间无统计学显著差异。PAI-2水平在对照组和患者中均低于检测限。然而,DIC病例中初始升高的D-二聚体复合物水平显著更高(p<0.01),且在治疗期间升高。在DIC患者中发现D-二聚体与TAT复合物值之间存在显著正相关(r = 0.68,p<0.001)。化疗期间TAT复合物和D-二聚体水平进一步升高,强烈提示存在高凝状态伴继发性纤溶激活,但在大多数情况下严重程度不足以表现为临床明显的DIC。